24Business
Bicara Therapeutics announces the first patients enrolled in Fortifi-Hn01, the main phase 2/3 of the clinical test of ficerafusp alpha in 1l repetitive/metastatic carcinoma of the squamous cell and neck cells
Bicara Therapeutics announces the first patients enrolled in Fortifi-Hn01, the main phase 2/3 of the clinical test of ficerafusp alpha in 1l repetitive/metastatic carcinoma of the squamous cell and neck cells
Source link
